{
  "id": "28f8c089fe2f4d63",
  "title": "Reviewing Carlsmed ( NASDAQ : CARL ) & Perspective Therapeutics ( NASDAQ : CATX ) ",
  "description": "20260114T050000Z",
  "content": "",
  "source": "dailypolitical.com",
  "source_url": "https://www.dailypolitical.com/2026/01/13/reviewing-carlsmed-nasdaqcarl-perspective-therapeutics-nasdaqcatx.html",
  "published_at": "20260114T050000Z",
  "fetched_at": "2026-01-15T00:21:56.842948+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.dailypolitical.com/2026/01/13/reviewing-carlsmed-nasdaqcarl-perspective-therapeutics-nasdaqcatx.html",
    "url_mobile": "",
    "title": "Reviewing Carlsmed ( NASDAQ : CARL ) & Perspective Therapeutics ( NASDAQ : CATX ) ",
    "seendate": "20260114T050000Z",
    "socialimage": "",
    "domain": "dailypolitical.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}